N/A N=210 Integrating Care After Exacerbation of COPD
Chronic Obstructive Pulmonary Disease
Primary: Number of Patients With Hospital Re-admission and Mortality — 84; 61 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
Diabetic Retinopathy
Primary: Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period — 35.0; 23.1 Percentage of participants
N/A N=70 Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Biliary Strictures Caused by Malignant Neoplasms
Primary: Number of Participants With Absence of Recurrent Biliary Obstruction — 62 Participants
N/A N=175 Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds
Nasolabial Folds in Chinese Population
Primary: Percentage of Responders, Defined by at Least 1-point Improvement From Baseline on the WSRS. — 72.9; 72.8 percentage of subjects
Phase 3 N=386 Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.74; -0.82 percentage of HbA1c
N/A N=27 MBCT Delivered Via Group Videoconferencing for ACS Patients With Elevated Depression Symptoms
Acute Coronary Syndrome · Depression · Myocardial Infarction
Primary: Number of Participants Reporting Changes After ACS — 3; 3; 10; 1 participants
Phase 2 N=104 Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome
Xerostomia · Sjogren's Syndrome
Primary: Overall Improvement Rate in Dry Mouth Symptoms — 26.0; 20.0; 44.0; 27.1 percentage of participants
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
N/A N=30 Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy
Vulvovaginal Atrophy
Primary: The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared…
Phase 1 N=12 This Study in Healthy Men Tests How the Body Takes up BI 1467335
Healthy
Primary: After the First Dose: Area Under the Concentration-time Curve of BI 1467335 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) of BI 1467335 (After…
Phase 1 N=48 This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects
Phase 2 N=52 Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill
Contraception
Primary: Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS) — 1.0; 0.7; 0.1; 0.3 changes in scores on a scale — p=0.26
N/A N=3,835 Red Cell Storage Duration and Outcomes in Cardiac Surgery
Blood Transfusion · Cardiac Surgery
Primary: Primary Aim is to Determine Whether Length of Storage of Red Blood Cells is Related to Postoperative Morbid Outcomes in Patients Undergoing Cardiac Surgery. — 360; 362…
Phase 4 N=60 Osimertinib Study in Indian Patients
Non Small Cell Lung Cancer (NSCLC)
Primary: Safety of Osimertinib — 60 Participants
Phase 2 N=88 Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
Anaemia
Primary: Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57 — 142.87; 143.03 Millimeters of…